Skip to content
How Venture Philanthropy Can Accelerate Drug Development episode artwork

Dec 31, 2014 19 min

How Venture Philanthropy Can Accelerate Drug Development

from RARECast

Prosensa, a biotechnology company developing a breakthrough therapy for the rare, fatal, genetic disease Duchenne muscular dystrophy suffered a big setback when disappointing, late-stage trial results of its lead therapeutic led its partner, GlaxoSmithKline, to return rights to the experimental drug in January 2014. Prosensa’s stock plummeted and the future of the company was uncertain. CureDuchenne, which had provided early funding for the company, stepped in once again. This time it made a $7 million commitment to restore the clinical programs and move the company forward. We spoke to Debra Miller, president and CEO of CureDuchenne about her experience with Prosensa, the recent news that BioMarin would acquire the company for up to $840 million, and the role venture philanthropists like her can play in accelerating the development of life saving drugs.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

How Venture Philanthropy Can Accelerate Drug Development

0:00 19:36

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of RARECast?

This episode is 19 minutes long.

When was this RARECast episode published?

This episode was published on December 31, 2014.

Can I download this RARECast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.